Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > 900 million dogs on planet earth

<< Previous

Bullboard Posts

Next >>

Comment by Bigginvestoron Mar 03, 2021 10:21am

95 Views

Post# 32704111

RE:900 million dogs on planet earth

losingmyshirt wrote: Garry Southan's work could benefit 900 million dogs. Can you imagine if the NO treatment is expanded to cover all breeds of dogs we will have a winner on our hands.
Just read the article. It's clear. TO THE MOON.

Buy more KLY. Buy more dogs. ready for liftoff.

l you were hateing now you Lovin the company .just be patient all you fools that are not patient it's ur own fault when this takes off

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec